中华内科杂志
中華內科雜誌
중화내과잡지
CHINESE JOURNAL OF INTERNAL MEDICINE
2015年
2期
106-110
,共5页
淋巴瘤,结外NK/T细胞%EB病毒核抗原1%潜伏膜蛋白1
淋巴瘤,結外NK/T細胞%EB病毒覈抗原1%潛伏膜蛋白1
림파류,결외NK/T세포%EB병독핵항원1%잠복막단백1
Lymphoma,extranodal NK-T-cell%EBV-determined nuclear antigen 1%Latent membrane protein 1
目的 检测鼻型结外NK/T细胞淋巴瘤(ENKL)患者血清EB病毒核抗原1(EBNA1)、潜伏膜蛋白1(LMP1),探讨其与ENKL的关系.方法 选取首都医科大学北京同仁医院2010年8月到2013年8月新诊断ENKL患者36例、健康对照者20例,以EBNA1、LMP1为目的基因,采用实时定量PCR方法分别检测ENKL患者治疗前后和健康对照者外周血EBNA1、LMP1.结果 治疗前,ENKL患者血清EBNA1中位数为1.9×104(0 ～ 11.0×104)拷贝/μl,健康对照组为8.0(0 ～43.8)拷贝/μl;ENKL患者LMP1中位数为3.9 ×103(118.3 ～24.0×103)拷贝/μl,健康对照组为3.3(0～33.3)拷贝/μl.治疗前ENKL患者EBNA1、LMP1均显著高于健康对照组(P均＜0.01).治疗后,ENKL患者血清EBNA1中位数为1.0×103(0 ～2.0×103)拷贝/μl,LMP1为300.8(0 ～825.7)拷贝/μl,两者较治疗前均显著降低(P＜0.05).治疗有效患者的治疗后EBNA1、LMP1中位数均低于治疗无效的患者(P＜0.05).治疗前ENKL患者EBNA1、LMP1与血清乳酸脱氢酶水平呈正相关(r=0.364、0.546,P=0.040、0.012).EBNA1、LMP1低于临界值(EBNA1:1.3×104拷贝/μl; LMP1:3.0×103拷贝/μl)患者的2年总生存率和无进展生存率优于EBNA1、LMP1高于临界值者,但差异无统计学意义(P均＞0.05).结论 (1)检测ENKL患者血清EBNA1和LMP1对评判治疗效果具有一定价值;(2)ENKL患者血清EBNA1、LMP1可反映肿瘤负荷.
目的 檢測鼻型結外NK/T細胞淋巴瘤(ENKL)患者血清EB病毒覈抗原1(EBNA1)、潛伏膜蛋白1(LMP1),探討其與ENKL的關繫.方法 選取首都醫科大學北京同仁醫院2010年8月到2013年8月新診斷ENKL患者36例、健康對照者20例,以EBNA1、LMP1為目的基因,採用實時定量PCR方法分彆檢測ENKL患者治療前後和健康對照者外週血EBNA1、LMP1.結果 治療前,ENKL患者血清EBNA1中位數為1.9×104(0 ～ 11.0×104)拷貝/μl,健康對照組為8.0(0 ～43.8)拷貝/μl;ENKL患者LMP1中位數為3.9 ×103(118.3 ～24.0×103)拷貝/μl,健康對照組為3.3(0～33.3)拷貝/μl.治療前ENKL患者EBNA1、LMP1均顯著高于健康對照組(P均＜0.01).治療後,ENKL患者血清EBNA1中位數為1.0×103(0 ～2.0×103)拷貝/μl,LMP1為300.8(0 ～825.7)拷貝/μl,兩者較治療前均顯著降低(P＜0.05).治療有效患者的治療後EBNA1、LMP1中位數均低于治療無效的患者(P＜0.05).治療前ENKL患者EBNA1、LMP1與血清乳痠脫氫酶水平呈正相關(r=0.364、0.546,P=0.040、0.012).EBNA1、LMP1低于臨界值(EBNA1:1.3×104拷貝/μl; LMP1:3.0×103拷貝/μl)患者的2年總生存率和無進展生存率優于EBNA1、LMP1高于臨界值者,但差異無統計學意義(P均＞0.05).結論 (1)檢測ENKL患者血清EBNA1和LMP1對評判治療效果具有一定價值;(2)ENKL患者血清EBNA1、LMP1可反映腫瘤負荷.
목적 검측비형결외NK/T세포림파류(ENKL)환자혈청EB병독핵항원1(EBNA1)、잠복막단백1(LMP1),탐토기여ENKL적관계.방법 선취수도의과대학북경동인의원2010년8월도2013년8월신진단ENKL환자36례、건강대조자20례,이EBNA1、LMP1위목적기인,채용실시정량PCR방법분별검측ENKL환자치료전후화건강대조자외주혈EBNA1、LMP1.결과 치료전,ENKL환자혈청EBNA1중위수위1.9×104(0 ～ 11.0×104)고패/μl,건강대조조위8.0(0 ～43.8)고패/μl;ENKL환자LMP1중위수위3.9 ×103(118.3 ～24.0×103)고패/μl,건강대조조위3.3(0～33.3)고패/μl.치료전ENKL환자EBNA1、LMP1균현저고우건강대조조(P균＜0.01).치료후,ENKL환자혈청EBNA1중위수위1.0×103(0 ～2.0×103)고패/μl,LMP1위300.8(0 ～825.7)고패/μl,량자교치료전균현저강저(P＜0.05).치료유효환자적치료후EBNA1、LMP1중위수균저우치료무효적환자(P＜0.05).치료전ENKL환자EBNA1、LMP1여혈청유산탈경매수평정정상관(r=0.364、0.546,P=0.040、0.012).EBNA1、LMP1저우림계치(EBNA1:1.3×104고패/μl; LMP1:3.0×103고패/μl)환자적2년총생존솔화무진전생존솔우우EBNA1、LMP1고우림계치자,단차이무통계학의의(P균＞0.05).결론 (1)검측ENKL환자혈청EBNA1화LMP1대평판치료효과구유일정개치;(2)ENKL환자혈청EBNA1、LMP1가반영종류부하.
Objective To explore the clinical significance of the serum Epstein-Barr virus determined nuclear antigen 1 (EBNA1)/latent membrane protein 1 (LMP1) in patients with extranodal NK/T-cell lymphoma,nasal type (ENKL).Methods The serum EBNA1 and LMP1 were detected by realtime PCR in 36 ENKL patients hospitalized in Beijing Tongren Hospital from August 2010 to August 2013.Twenty healthy volunteers were recruited as controls.Results The median serum EBNA1 was 1.9 × 104 (ranged from 0 to 11.0 × 104) copies/μl in ENKL patients and 8.0 (ranged from 0 to 43.8) copies/μl in healthy volunteers.The median serum LMP1 was 3.9 × 103 (ranged from 118.3 to 24.0 × 103) copies/μl in ENKL patients and 3.3 (ranged from 0 to 33.3) copies/μl in healthy volunteers.Both EBNA1 and LMP1 were higher in ENKL patients than healthy volunteers (all P ＜ 0.01).The median EBNA1 and LMP1 in ENKL patients posttreatment were 1.0 × 103 (ranged from 0 to 2.0 × 103) copies/μl and 300.8(ranged from 0 to 825.7) copies/μl respectively,which were both significantly decreased than pretreatment (all P ＜ 0.05).The EBNA1 and LMP1 were decreased in effective treatment group versus ineffective treatment group (P ＜0.05).The serum EBNA1 and LMP1 were positively correlated with lactic dehydrogenase (LDH) level (r =0.364,0.546 ; P =0.040,0.012).Conclusions (1) The measurement of EBNA1/LMP1 may be useful in evaluating the therapeutic effect.(2)The serum EBNA1/LMP1 may reflect the tumor load in ENKL patients.
